The presence of human immunodeficiency virus
athy (4, 6, 8) . Intra-blood-brain barrier synthesis of HIV- specific antibody (HIV-Ab) has been documented in persons with AIDS-related neurological symptoms (9) and in asymptomatic seropositive individuals (10) .
HIV antigen (HIV-Ag) appears transiently in serum preceding or accompanying seroconversion and is present persistently in the serum of a majority of AIDS patients (11) . In cerebrospinal fluid (CSF), lIIV-Ag appears to be associated with progressive encephalopathy in children (12) . In the present study, we report the correlation between HIV-Ag expression in CSF of humans and experimentally infected chimpanzees, intra-blood-brain barrier production of HIVAb, and clinical disease.
MATERIALS AND METHODS
Serum and CSP Specimens. CSF and serum were tested from six adult homosexual patients with AIDS (presenting with opportunistic infections, Kaposi sarcoma, or both) and one patient with AIDS-related complex (ARC) (hospitalized in the Academic Medical Center of the University of Amster- dam), and from seven adult HIV-seropositive homosexual men without AIDS or ARC. Eleven children (ranging in age from 1 to 6 years) with AIDS or ARC, hospitalized at the University of Medicine and Dentistry of New Jersey, were also studied. All but three children (Table 1 , patients 1, 3, and 16) were born to intravenous drug-using HIV-Ab seropositive mothers; patients 1 and 3 were infected by blood transfusion and no risk factor could be identified in patient 16, although the mother was HIV-Ab seropositive.
Eight chimpanzees experimentally infected with HIV were also included in the study (3) . Seroconversion to HIV occurred 3-6 weeks after inoculation with brain tissue from an AIDS patient (chimpanzee A3), with plasma from AIDS patients (chimpanzees A3B and A3C), with HIV (chimpanzees A3D, A3E, A22, and A86B), or with blood from an experimentally infected chimpanzee (A274B). None of the chimpanzees was clinically ill, and all remained healthy 2 years after inoculation. Paired samples of serum and CSF were stored at -20'C until testing.
HIV Antibody Assays. An ELISA using purified HIV (strain HTLV-IIIB) as antigen (Vironostika, Organon, Oss, The Netherlands) was used to detect anti-HIV antibodies (13) . Specificity of the antibody for HIV as confirmed by immunoblotting (14) was defined as reactivity with the major core protein (p24) and/or the transmembrane protein (gp4l).
Antibodies against the HIV envelope protein (env) were measured by using a competitive enzyme immunoassay ( Intra-Blood-Brain Barrier Synthesis of HIV Envelope and Core-Specific Antibodies. Immunoblot analysis of HIV-Ab in serum and CSF revealed that the IgG response in HIV-Agpositive AIDS patients was primarily to gp4l, while in the HIV-Ag-negative ARC patients and asymptomatic HIV-Ab seropositive men antibodies to p18 and p24 were also present, along with gp4l (Fig. 3) . In one patient, reactivity in the serum was predominantly to gp4l and in the CSF to p24 (Fig.  3, patient 8 ). Subsequently, intra-blood-brain barrier synthesis of HIV env-specific antibodies was studied in four AIDS patients with progressive encephalopathy, in three AIDS patients without progressive encephalopathy, and in four asymptomatic HIV-Ab seropositive individuals. Three of four AIDS patients with progressive encephalopathy showed intra-blood-brain barrier synthesis of antibodies to HIV env proteins, as did one of three AIDS patients and two of four asymptomatic controls without progressive encephalopathy (Table 2) .
Immunoblot analysis of paired samples of serum (S) and CSF from HIV-inoculated chimpanzees. A human control serum (C) recognizing the pol gene product p65/pS1, the env gene product gp4l, and the gag gene products p24 and p18 is indicated on the left. HIV antigen data are represented at the bottom of the figure. HIV-Ag in PEG Supernatant and Precipitate. The presence of HIV-Ag in supernatants and pellets of PEG precipitates of serum and CSF was tested in three HIV-Ag seropositive and three HIV-Ag seronegative individuals without progressive encephalopathy with high titers of HIV env-specific antibodies in their serum (Table 3) . HIV-Ag was present in both free and complexed form in sera of all three HIV-Ag seropositive individuals. None of these three men had HIV-Ag present in any form in the CSF. In each of two HIV-Ag negative asymptomatic men, HIV-Ag was detected in complexed form in the serum and CSF, respectively, after dissociation with 6 M guanidine. (S) and CSF from patients with AIDS (7-12) and ARC (18) , and from asymptomatic HIV-seropositive controls (20) (21) (22) (23) . The patient numbers correspond to the numbers in Table 1 . At the left the pol gene products p65/pSi and p33, the env gene product gp4l, and the gag gene products p24 and p18 are indicated. At the bottom of the figure the corresponding HIV antigen data are indicated.
DISCUSSION
Presence of HIV-Ag in serum correlates with an advancing disease state in HIV infection. HIV antigenemia in non-AIDS patients reflects impending AIDS (22) or, when transient, indicates acute infection (11) . HIV-Ag was not observed in serum of HIV-Ab seropositive chimpanzees without clinical disease taken over a year after infection, a finding resembling observations in asymptomatic HIV-Ab seropositive men. HIV-Ag in CSF was seen only in HIV antigenemic patients with AIDS and was strongly associated with progressive encephalopathy, especially in children. HIV-Ag in the CSF of an AIDS patient without progressive encephalopathy may be a harbinger of future brain disease. Intra-blood-brain barrier synthesis of HIV-Ab was detected in the majority of patients with AIDS and in HIV-infected subjects without AIDS independent of neurological symptoms. This is in agreement with previous reports (10) . HIV env-specific B-cell clones were identified in approximately one-half of the patients with intra-blood-brain barrier synthesis of HIV-Ab.
An excess of HIV-Ag in uncomplexed form was demonstrated in serum of AIDS patients. In only one HIV-Ab seropositive individual without HIV-Ag detected either in untreated serum or CSF (Table 3, patient 6) was HIV-Ag found in the PEG precipitate of CSF, indicating the presence of HIV-Ag in an immune complex. Because HIV-Ag was rarely detected in PEG precipitates dissolved in PBS (J. M. A. Lange, D.A.P., and J.G., unpublished data), we tentatively conclude that the HIV-Ag assay detects primarily HIV-Ag in the uncomplexed form.
These data indicate that excess HIV-Ag directly detectable in CSF is strongly associated with progressive encephalopathy. We have previously shown (11) that HIV-Ag may be present transiently in CSF following acute HIV infection without neurological symptoms. Following virus entry into the brain, and possibly viral replication, local antibody production is initiated. Persistence of HIV-Ag in CSF appears to reflect HIV gene expression in the brain, causing progressive encephalopathy in most children and less frequently in adults. 
